SAN FRANCISCO--(BUSINESS WIRE)--Nuvelution Pharma, Inc., today announced the appointment of Milena Kanova-Petrova, M.D., as Senior Vice President of Operations effective immediately. Dr. Kanova-Petrova brings more than 21 years of experience in project management, site management, business development, clinical leadership, country operations and medical services to the Nuvelution management team.
“Milena’s experience working with strategic and operational teams planning and implementing strategies for clinical trials in various indications and in all clinical development phases will add substantial value to our team,” said Sandy Zweifach, President and CEO of Nuvelution Pharma. “Her experience in consulting on numerous developmental programs both as strategy lead, operational expert, and a medical adviser will be instrumental in providing longer-term strategies for the building, growth and financial performance of the units under her leadership.”
Prior to Nuvelution, Dr. Kanova-Petrova served for 21 years at IQVIA in numerous positions with increasing responsibility. Most recently, she was Vice President of Clinical Project Leadership, Global Therapeutic Area Head for CNS at IQVIA. Other positions she held at IQVIA included Senior Director of Project Management, Therapeutic Strategy Lead in Internal Medicine, Immunology, and Rare Diseases, Global Operations Head for General Internal Medicine, and Clinical Operations Manager and Country Manager. She was also in charge of setting up new offices and clinical research services in Central and Eastern Europe and the Middle East. Dr. Kanova-Petrova acquired her M.D. degree from the Medical University of Sofia and held a residency position in neurosurgery in the Medical University of Pleven, Bulgaria.
“I look forward to working with the distinguished team at Nuvelution and applying my expertise to further advance the Company’s late-stage clinical assets and strive towards developing products to bring to market,” said Dr. Kanova-Petrova.
About Nuvelution Pharma
Nuvelution leverages its extensive knowledge, experience and relationships in the pharma and biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring essential medicines to patients. For more information, please visit www.nvtpharma.com.